All In Biotech

NDA 020818 · Novartis

Diovan Hct

Hydrochlorothiazide, Valsartan · Oral · Thiazide Diuretic; Angiotensin 2 Receptor Blocker

Last checked: Nov 20, 2026Latest source record: Aug 20, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1998

Mar 6, 1998

Approved uses

4

Original approval plus efficacy supplements

Registered trials

450

138 Phase 3, 14 recruiting

FAERS reports

13,539

10,407 serious, 1,385 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: FETAL TOXICITY When pregnancy is detected, discontinue Diovan HCT as soon as possible. (5.1) Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. (5.1) WARNING: FETAL TOXICITY See full prescribing information for complete boxed warning. When pregnancy is detected, discontinue Diovan HCT as soon as possible. ( 5.1 ) Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. ( 5.1 )

What it is approved for

From the label in effect Feb 13, 2026.

Diovan HCT (valsartan and hydrochlorothiazide, USP) is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including hydrochlorothiazide and the angiotensin II receptor blocker (ARB) class to which valsartan principally belongs. There are no controlled trials demonstrating risk reduction with Diovan HCT. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality have also been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular...

Mechanism: Angiotensin II is formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzyme (ACE, kininase II). Angiotensin II is the principal pressor agent of the renin-angiotensin system, with effects that include vasoconstriction, stimulation of synthesis and release of aldosterone, cardiac stimulation, and renal reabsorption of sodium. Valsartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT 1 receptor in many tissues, such as vascular smooth muscle and the adrenal gland. Its action...

Therapeutic areas: Cardiovascular and metabolic

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

5 products under this application
  • DIOVAN HCT · HYDROCHLOROTHIAZIDE 25MG; VALSARTAN 160MG · TABLET, ORAL · Prescription · TE AB
  • DIOVAN HCT · HYDROCHLOROTHIAZIDE 12.5MG; VALSARTAN 80MG · TABLET, ORAL · Prescription · TE AB
  • DIOVAN HCT · HYDROCHLOROTHIAZIDE 12.5MG; VALSARTAN 320MG · TABLET, ORAL · Prescription · TE AB
  • DIOVAN HCT · HYDROCHLOROTHIAZIDE 12.5MG; VALSARTAN 160MG · TABLET, ORAL · Prescription · TE AB
  • DIOVAN HCT · HYDROCHLOROTHIAZIDE 25MG; VALSARTAN 320MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Hydrochlorothiazide" as an intervention, any sponsor and status, largest first.

All 450 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • blood pressure increased822
  • dizziness803
  • hypertension780
  • drug ineffective748
  • headache712
  • fatigue691
  • nausea656
  • dyspnoea614
  • malaise570
  • fall561
  • pain532
  • death501

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004186
2005309
2006343
2007597
2008777
20091,278
20101,089
20111,310
20121,447
2013793
2014647
2015732
2016757
2017521
2018667
2019468
2020394
2021288
2022232
2023222
2024167
2025181
2026134

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Diovan HCT (Valsartan/Hydrochlorothiazide)

2024 spending

$6.5M

Beneficiaries

1,777

7,543 claims

Per beneficiary

$3,649

$11.92 per unit

View as table
YearSpending
2020$10,613,791
2021$8,763,838
2022$7,843,411
2023$7,652,064
2024$6,484,123

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 2,366 on PubMed

Sponsor: Novartis

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.